Calciphylaxis Treatment Market – Insights
Calciphylaxis or Calcific Uremic Arteriolopathy (CUA) is the most severe form of cardiovascular calcification in dialysis patients. It starts with a calcification of small peripheral vessels and quickly spreads in the body. Moreover, people suffering from calciphylaxis have an imbalance in calcium metabolism, which causes calcium to be deposited in arterioles, which eventually leads to the formation of blood clots in the arterioles. Blood clots can cause fat tissues and skin to be deprived of oxygen and nourishment.
According to a data published by National Center for Biotechnology Information (NCBI) 2014 report, calciphylaxis affects around 4% of patients in the late stage of chronic kidney disease and 55% of patients with calciphylaxis die within a year of diagnosis and suffer from painful skin ulcers and a high risk of infection. No effective treatment for calciphylaxis is currently available and its causes are unknown. However, patients suffering from this disease are usually treated with intensive care, including wound management. The occurrence of calciphylaxis is associated with hyperthyroidism.
The global calciphylaxis treatment market size was valued at US$ 1,097.7 million in 2017 and is expected to witness a CAGR of 9.6% over the forecast period (2018 – 2026).
Global Calciphylaxis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
Increasing clinical trials in the field of calciphylaxis is expected to drive the calciphylaxis treatment market revenue
According to the Journal of General Internal Medicine 2014 study, calciphylaxis has an increasing incidence trend and a 50% mortality rate within the first year of onset. High prevalence of kidney disease is a major factor for incidences of calciphylaxis. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, over 661,000 Americans had kidney failure and 468,000 of these patients were on dialysis.
Various academic research institutes and companies are focused on developing suitable treatment for calciphylaxis. For instance in March 2018, Sanifit successfully completed a Phase II trial of the first effective treatment for calciphylaxis. Moreover, in 2014, researchers at the National Kidney Foundation reported successful application of intravenous (IV) pamidronate to treat calciphylaxis in patients with End-Stage Renal Disease (ESRD).
Calciphylaxis Treatment Market Restraints
Lack of an appropriate treatment for calciphylaxis is a major factor hindering growth of the global calciphylaxis treatment market. However, increasing research to develop a suitable treatment for the condition is expected to drive growth of the market.
Calciphylaxis Treatment Market - Regional Insights
On the basis of region, the global calciphylaxis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America calciphylaxis treatment market is expected to foresee major revenue share, owing to increasing government support and funding to treat calciphylaxis patients. According to the National Kidney Disease Education Program study 2015, in the U.S., treatment of chronic kidney disease surpasses US$ 48 billion, annually and the ESRD program consumes 6.7% of the total Medicare budget to care for less than 1% of the covered population.
Asia Pacific calciphylaxis treatment market is expected to witness growth at a significant CAGR, owing to increasing expenditure in treatment of kidney diseases coupled with high prevalence of kidney diseases with diabetes and growing geriatric population base. For instance, according to the National Kidney Disease Education Program study 2015, in Australia, treatment for all current and new cases of kidney failure by 2020 is expected to cost around US$ 12 billion. Moreover, annual cost of dialysis per patient, annually varies between US $35,000 and 55,000 depending on the type of treatment.
Global Calciphylaxis Treatment Market Share (%) Analysis, By Region 2017
Source: Coherent Market Insights Analysis (2018)
Calciphylaxis Treatment Market - Competitive Landscape
Key players operating in the global calciphylaxis treatment market include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.
Calciphylaxis or calcific uremic arteriolopathy is a syndrome of vascular calcification, thrombosis, and skin necrosis. It mostly occurs in patients with end-stage kidney disease or kidney transplant. Calciphylaxis results in chronic non-healing wounds and is usually fatal. It has a high mortality rate, owing to cardiovascular disease and sepsis caused due to infected skin ulcers. The exact pathogenetic mechanisms of the disease is not known. Most patients with the condition have abnormalities in blood-clotting factors. Multiple interventions are used to treat calciphylaxis, including restoring oxygen and blood flow to the skin, decreasing calcium deposits, and intensive wound treatment.
High prevalence of kidney diseases and increasing number of clinical trials in the field of calciphylaxis treatment are major factors expected to drive growth of the calciphylaxis treatment market. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, the overall prevalence of chronic kidney diseases in the U.S. was around 14% of total population.
Calciphylaxis has no approved treatment, which has led to increasing number of clinical trials and research, which is expected to fuel growth of the market. For instance, in March 2015, the Multidisciplinary Calciphylaxis Program launched the first randomized trial for treatment of calciphylaxis with research focus on the role of vitamin K in the treatment of the disease.
Lack of an appropriate treatment for calciphylaxis is a major obstacle in the calciphylaxis treatment market growth. However, key players in the market are focused on identifying the root cause of the disease and its associated treatment in order to gain market share. For instance, according to a study published by the American Journal of Nephrology, in June 2018, apixaban, an anticoagulant used to treat venous thromboembolic events, can be a safe and effective alternative to warfarin in patients with End-Stage Renal Disease (ESRD) on dialysis suffering from calciphylaxis.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 24 market data tables and 21 figures on "Calciphylaxis Treatment Market” - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.